We live in the world of high technologies and innovations which have already become usual things for us – the representatives of an advanced generation. These innovations surround us everywhere, especially the medical sphere and help us fight the most deadly and dangerous diseases.
It would be worth mentioning such a significant progress in Hepatitis C sphere. This progress was achieved with the help of Sovaldi. Sovaldi is the brand name for Sofosbuvir, a nucleotide analog inhibitor of HCV NS5B polymerase. Sovaldi tablets are indicated for oral administration. Each tablet comes in the form of 400 mg of Sofosbuvir (active component). Sovaldi efficacy has been extremely recognized in subjects with HCV genotype 1, 2, 3 or 4 infections, including those individuals with hepatocellular carcinoma and those patients awaiting liver transplantation and those suffering from HCV/HIV-1 co-infection.
Sovaldi should be prescribed together with Ribavirin or Peginterferon Alfa/Ribavirin.
This drug showed curing rates in Hepatitis C in more than 90% of those for whom it has been prescribed. It does not cause any alarming and serious adverse reactions encouraging the patient continue the treatment and reach the best results in the disease fight.
Hepcinat is the analogue of the brand medication Sovaldi, manufactured in India under the license given by Gilead Sciences Inc. So, we may see that the active ingredient of Hepcinat is the same as the one of Sovaldi – Sofosbuvir 400 mg. Hepcinat is manufactured using the patented technology and preserving pharmacokinetic bioequivalence with the original Sovaldi.
That why, we can say that the obvious difference is the very name given to the marketed drug. Hepcinat is sold in low-developed countries with low quality of living.
Such drugs sold without brand names are altogether, less costly than brand-name drugs, even despite the fact that they are chemically similar in nature to brand-name drugs and comply with the same strict standards of the FDA for safety, purity and effectiveness. Usually the high price phenomenon of brand medicine is defined by the intention to compensate the investigation, development, license, marketing strategy, and advertising costs.